Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 275.00 GBp
Change Today 0.00 / 0.00%
Volume 0.0
EHP On Other Exchanges
As of 11:35 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

epistem holdings plc (EHP) Snapshot

275.00 GBp
Previous Close
275.00 GBp
Day High
275.00 GBp
Day Low
275.00 GBp
52 Week High
07/4/14 - 337.50 GBp
52 Week Low
03/30/15 - 225.00 GBp
Market Cap
Average Volume 10 Days
-0.30 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for EPISTEM HOLDINGS PLC (EHP)

Related News

No related news articles were found.

epistem holdings plc (EHP) Related Businessweek News

No Related Businessweek News Found

epistem holdings plc (EHP) Details

Epistem Holdings Plc, a biotechnology and personalised medicine company, provides pre-clinical testing, pharmacogenomic biomarker, and diagnostic testing services to the biotechnology and pharmaceutical industries in Europe, the United States, and Asia. It operates through three divisions: Preclinical Research Services, Personalised Medicine, and Novel Therapies. The Preclinical Research Services division provides preclinical efficacy testing, immunohistochemistry services, and cell biology expertise in the areas of oncology, oncology supportive care, inflammatory bowel disease, rheumatoid arthritis, and dermatology. The Personalised Medicine division offers sensitive molecular measures of biological processes that enhance precision in drug development and disease treatment. This division discovers, develops, and translates biomarkers for clinical drug development and companion diagnostics; and offers Genedrive, a molecular diagnostic device used in bacterial, viral, fungal, and somatic mutations disease identification. The Novel Therapies division discovers and develops regulators of epithelial stem cells and tissues. Epistem Holdings Plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.

71 Employees
Last Reported Date: 12/15/14
Founded in 2000

epistem holdings plc (EHP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 302.0K GBP
Co-Founder, Managing Director of Contract Res...
Total Annual Compensation: 107.3K GBP
Chief Financial Officer, Finance Director, Co...
Total Annual Compensation: 133.1K GBP
Chief Operating Officer of Diagnostics and Di...
Total Annual Compensation: 62.5K GBP
Compensation as of Fiscal Year 2014.

epistem holdings plc (EHP) Key Developments

EpiStem Holdings Plc Announces Directorate Change

Epistem Holdings Plc announced that Dr. Ian Gilham has been appointed as non-executive Chairman of Epistem, succeeding David Evans who also retires as a Director of the company.

EpiStem Holdings Plc Announces the Signing of a Licensing Agreement with Cancer Research Technologies and Newcastle University

Epistem Holdings Plc announced the signing of a licensing agreement with Cancer Research Technologies (CRT) and Newcastle University for access to and development of patient derived Acute Lymphoblastic Leukemia (ALL) Primagraft samples for commercial use. This agreement builds upon Epistems expertise with cell line based disseminated models of leukemia, and will further enhance the Company's ability to support pre-clinical therapeutic evaluation in haematological disease. The licensed Primagraft models include a range of fully cytogenetically characterized samples, with complete clinical history. In addition to FACs based methodologies, several of these systemic Primagraft models have been stably lentivirally transduced with a luciferase vector allowing monitoring of in-life treatment responses and evaluation of disease severity using Epistems Bruker In Vivo Xtreme Optical imaging system.

EpiStem Holdings Plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2014

EpiStem Holdings Plc reported unaudited consolidated earnings results for the six months ended December 31, 2014. Revenue was £1.7 million against £2.5 million last year. Operating loss was £1.9 million against £0.7 million last year. Loss on ordinary activities before taxation tax was £2.2 million against £0.7 million last year. Total comprehensive loss was £1.9 million against £0.6 million last year. Basic and diluted loss per share was 18.6 pence against 6.0 pence last year. Increased levels of investment and headcount in Personalised Medicine (Genedrive®) programme gave rise to the company’s reported loss. Net cash flow from operating activities was £0.9 million against net cash outflow from operating activities of £0.03 million last year. Acquisition of fixed assets was £0.6 million against £0.7 million last year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EHP:LN 275.00 GBp 0.00

EHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EHP.
View Industry Companies

Industry Analysis


Industry Average

Valuation EHP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPISTEM HOLDINGS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at